NewAmsterdam Pharma (NAMS) Goodwill & Intangibles (2022 - 2026)

NewAmsterdam Pharma has disclosed Goodwill & Intangibles across 5 years of filings, most recently posting $375000.0 for Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $375000.0, down 25.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $375000.0 (down 25.3% YoY), and the FY2025 annual result was $407000.0, down 23.78% from the prior year.
• Goodwill & Intangibles came in at $375000.0 for Q1 2026 at NewAmsterdam Pharma, down from $407000.0 in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $84.8 million in Q4 2022 to a low of $88887.8 in Q2 2023.
• The 5-year median for Goodwill & Intangibles is $478000.0 (2024), against an average of $7.5 million.
• Across the five-year window, Goodwill & Intangibles slumped 99.8% in 2023 and soared 509.76% in 2024, its largest moves.
• NewAmsterdam Pharma's Goodwill & Intangibles stood at $84.8 million in 2022, then plunged by 99.8% to $170000.0 in 2023, then jumped by 214.12% to $534000.0 in 2024, then decreased by 23.78% to $407000.0 in 2025, then fell by 7.86% to $375000.0 in 2026.
• The last three Goodwill & Intangibles figures came in at $375000.0 (Q1 2026), $407000.0 (Q4 2025), and $439000.0 (Q3 2025), per Business Quant data.